Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Schizophrenia01:17

Schizophrenia

Schizophrenia, a term introduced by Swiss psychiatrist Eugen Bleuler in 1911, describes a severe psychological disorder marked by profound disruptions in attention, thought processes, language, emotion, and interpersonal relationships. The core feature of schizophrenia is psychosis — a state characterized by a fundamental detachment from reality. This disconnection manifests through distorted logic, impaired perception, and atypical behavior, severely affecting the lives of those diagnosed.
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Biological Causes of Schizophrenia01:29

Biological Causes of Schizophrenia

Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
Positive Symptoms of Schizophrenia: Hallucinations and Delusions01:30

Positive Symptoms of Schizophrenia: Hallucinations and Delusions

Schizophrenia is a complex mental health disorder that can manifest with various positive symptoms, including thought, movement, and behavior disorders. These symptoms significantly disrupt cognitive and motor functions, leading to profound effects on an individual's ability to engage with the world.
Thought Disorders
Disorganized and unusual thought processes mark thought disorders in schizophrenia. One key feature is disorganized speech, where an individual's conversation includes loosely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Defining score interpretation thresholds for clinical outcome assessments: a review of terminology and reporting recommendations.

Journal of patient-reported outcomes·2025
Same author

Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab.

Osteoarthritis and cartilage open·2022
Same author

Physician and patient perceptions of surgical procedures for osteoarthritis of the knee in the United States, Europe, and Japan: results of a real-world study.

BMC musculoskeletal disorders·2022
Same author

Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data.

Scandinavian journal of rheumatology·2022
Same author

Care pathways in atopic dermatitis: a retrospective population-based cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Related Experiment Video

Updated: Jun 30, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

The distribution of body mass index among individuals with and without schizophrenia.

D B Allison1, K R Fontaine, M Heo

  • 1Obesity Research Center, St. Luke's/Roosevelt Hospital, Columbia University College of Physicians & Surgeons, New York, NY 10025, USA. Dba8@columbia.edu

The Journal of Clinical Psychiatry
|April 30, 1999
PubMed
Summary
This summary is machine-generated.

Individuals with schizophrenia, particularly women, show similar or higher obesity rates compared to those without the condition. This highlights concerns about antipsychotic drug-induced weight gain.

More Related Videos

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Clinical Anthropometrics and Body Composition from 3-Dimensional Optical Imaging
06:48

Clinical Anthropometrics and Body Composition from 3-Dimensional Optical Imaging

Published on: June 7, 2024

Related Experiment Videos

Last Updated: Jun 30, 2026

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
05:14

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Clinical Anthropometrics and Body Composition from 3-Dimensional Optical Imaging
06:48

Clinical Anthropometrics and Body Composition from 3-Dimensional Optical Imaging

Published on: June 7, 2024

Area of Science:

  • Public Health
  • Psychiatry
  • Epidemiology

Background:

  • Obesity is a significant public health concern.
  • Antipsychotic medications are known to cause weight gain.
  • Understanding BMI distribution in schizophrenia is crucial for managing health risks.

Purpose of the Study:

  • To compare body mass index (BMI) distributions in individuals with and without schizophrenia.
  • To contextualize the weight gain effects of antipsychotic drugs.

Main Methods:

  • Utilized data from the National Health Interview Survey (NHIS), a ziprasidone drug trial, and the National Health and Nutrition Examination Survey III (NHANES III).
  • Analyzed age-adjusted BMI data across different datasets and demographic groups.

Main Results:

  • Women with schizophrenia exhibited significantly higher mean BMIs than women without schizophrenia in the NHIS data (27.36 vs. 24.50).
  • Men with schizophrenia showed comparable mean BMIs to men without schizophrenia across all datasets.
  • BMI distributions were similar between genders with and without schizophrenia in the ziprasidone trial and NHANES III data.

Conclusions:

  • Individuals with schizophrenia are generally as or more obese than those without the condition.
  • Weight gain associated with antipsychotic agents is a significant concern for many patients.
  • Further research into BMI disparities and management strategies is warranted.